Axovant Gene Therapies (NASDAQ: AXGT) announced the grant of an Orphan Drug Designation for AXO-AAV-GM1, the Company’s investigational gene therapy for the treatment of GM1 gangliosidosis. AXO-AAV-GM1 is capable of restoring the β-galactosidase enzyme activity by delivering a functional copy of the dysfunctional GLB1 gene,...
Foamix and Menlo Therapeutics have signed a definitive merger agreement to form a biopharmaceutical Company focused on dermatological conditions. The combined entity will have a robust portfolio of diversified candidates, including an approved product and three late-stage clinical candidates. Foamix’s AMZEEQ™ (minocycline) topical foam, 4%, recently...
The International Energy Agency predicts that the Electronic Vehicles which stand at 3 million today will grow to 125 million by 2030. The Global Electric Vehicle market is all set to compete with the internal combustion engine (ICE) vehicles in the next five year, accounting...
Obseva (NASDAQ: OBSV), a biopharmaceutical Company focused on women’s reproductive health announced the discontinuation of nolasiban (OBE001), an oral oxytocin receptor antagonist intended for women undergoing embryo transfer (ET) following in-vitro fertilization (IVF). The candidate, though well-tolerated, failed to meet the primary endpoint of an increase...
Conformis Inc (NASDAQ: CFMS), a medical technology company dealing in Knee and Joint replacements, has announced the clearance of its next generation Conformis Hip System by the FDA. The Company’s leading-edge patient-specific arthroplasty joint replacement implants, moulded to suit each patient’s unique anatomy, are developed...
Forewarn, Red Violet Company (NASDAQ: RDVT), a leading consumer insight solution provider, announced that it has entered into a partnership agreement with the Central Illinois Board of REALTORS®, to make its cutting-edge risk assessment and customer due diligence technology available to over 500+ REALTOR® members...
Enlivex Therapeutics (NASDAQ: ENLV), a Company focused on developing allogenic therapies for immune system rebalancing, announced positive interim efficacy data from its ongoing Phase Ib clinical trial in patients with severe sepsis. The analysis in based on data collated from 43 patients with severe sepsis,...
Cyclerion Therapeutics (NASDAQ: CYCN), a clinical-stage Company, announced the failure of its drug candidate praliciguat in meeting the primary endpoints in two separate clinical studies, in diabetic nephropathy (DN) and heart failure with preserved ejection fraction (HFpEF). Praliciguat is a soluble guanylate cyclase (sGC) stimulator...
Amyotrophic Lateral Sclerosis (ALS) or Lou Gehrig’s disease is a progressive neurodegenerative disease, characterized by the atrophy of nerve cells in brain and spinal cord, leading to hardening and scarring in the affected region. As the disease progresses, patients gradually lose the functioning of muscles,...
Infinera (NASDAQ: INFN), a leading optical transmission solution provider, announced that its 7300 Multi-haul Transport Platform, mTera Universal Transport Platform, and Transcend software-defined networking (SDN) solution were adapted by Gtd, a Chilean multi-service telecommunications provider with operations in Chile, Colombia, Peru, and Spain. The systems will be used...
